Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Poor Graft Function

Interventions: Biological: Dose escalation
Biological: Dose extension

First Posted Date: 2025-01-27

Last Posted Date: 2025-03-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 15

Registration Number: NCT06792682

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, China, Tianjin, Tianjin, China

A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant Patients

Not Applicable

Not yet recruiting

Conditions: Hematologic Malignancy
Hematopoietic Stem Cell Transplant

First Posted Date: 2025-01-24

Last Posted Date: 2025-01-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 98

Registration Number: NCT06792630

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

Phase 2

Recruiting

Conditions: AML (Acute Myelogenous Leukemia)

Interventions: Drug: Avapritinib, azacitidine, Venetoclax

First Posted Date: 2025-01-20

Last Posted Date: 2025-01-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06783790

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

Phase 1

Not yet recruiting

Conditions: Immune Thrombocytopenia
Treatment

Interventions: Drug: nicotinamide adenine dinucleotid/nicotinamide mononucleotide

First Posted Date: 2025-01-15

Last Posted Date: 2025-01-15

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06776510

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

Phase 2

Not yet recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: daunorubicin, cytarabine liposomes
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 90

Registration Number: NCT06770257

A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Phase 1

Not yet recruiting

Conditions: Autoimmune Hemolytic Anemia
Anti-CD19 STAR T-cell Therapy
Failure ≥3 Lines of Therapies

Interventions: Biological: YTS109

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 7

Registration Number: NCT06770504

Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia

Phase 2

Not yet recruiting

Conditions: Aplastic Anaemia
HSCT
TBI
Old Age

Interventions: Drug: reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06769568

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Not Applicable

Not yet recruiting

Conditions: AL Amyloidosis

Interventions: Drug: CM-336 BCMA/CD3 bispecific antibody

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06769555

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia ALL
Childhood Leukemia, Acute Lymphoblastic
B Cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions: Drug: Blinatumomab (Group A)
Drug: Blinatumomab (Group B)
Drug: Venetoclax (nonRand Group)

First Posted Date: 2025-01-08

Last Posted Date: 2025-02-07

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 1800

Registration Number: NCT06764238

Locations: 🇨🇳
Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China
🇨🇳
Anhui Provincial Children's Hospital, Hefei, Anhui, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 23 locations

Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML

Not Applicable

Not yet recruiting

Conditions: AML

Interventions: Drug: Mitoxantrone Hydrochloride Liposome combined with BU/Cy

First Posted Date: 2025-01-06

Last Posted Date: 2025-01-06

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06758726

Home Terms & Conditions Privacy Policy